Login to Your Account



Zeltia Mulls Options Following EU Rejection Of Sarcoma Drug

By Cormac Sheridan


Wednesday, July 30, 2003
Spanish firm Zeltia SA is considering its options following the failure last week of its drug development subsidiary PharmaMar SA to obtain European Union marketing approval for Yondelis (trabectedin) as a third-line treatment for soft tissue sarcoma. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription